Elbasvir
drugOn this page
Also known as Elbasvir component of zepatierMK-8742
Summary
Elbasvir (CHEMBL3039514) is an approved small-molecule antiviral drug (ATC J05AP10); indicated across 4 conditions including chronic hepatitis c virus infection and viral infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J05AP10
- Indications: 4 conditions
- Clinical trials: 43
- Chemistry: 882 Da · C49H55N9O7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3039514 |
| Name | Elbasvir |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 71661251 |
| ChEBI | CHEBI:132967 |
| ATC | J05AP10 |
| Molecular formula | C49H55N9O7 |
| Molecular weight | 882 |
| InChIKey | BVAZQCUMNICBAQ-PZHYSIFUSA-N |
SMILES: CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@H](C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC
IUPAC name: methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
ChEBI definition: A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.
Pharmacological roles (ChEBI): antiviral drug, hepatoprotective agent, hepatitis C virus nonstructural protein 5A inhibitor.
Also known as: Elbasvir, Elbasvir component of zepatier, MK-8742, ELBASVIR, elbasvir
Patent coverage: 343 distinct patent families (828 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 808 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic hepatitis C virus infection | 4 | MONDO:0005354 | EFO:0004220 |
| viral infectious disease | 4 | MONDO:0005108 | EFO:0000763 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| viral hepatitis | 1 | MONDO:0006011 | EFO:0004196 |
Clinical trials
Total trials: 43.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 10 |
| PHASE2 | 10 |
| PHASE4 | 9 |
| Not specified | 8 |
| PHASE2/PHASE3 | 3 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02902120 | PHASE4 | COMPLETED | HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant |
| NCT02940691 | PHASE4 | TERMINATED | Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs |
| NCT02945150 | PHASE4 | COMPLETED | Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant |
| NCT03022006 | PHASE4 | UNKNOWN | Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C |
| NCT03098121 | PHASE4 | COMPLETED | Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection |
| NCT03105349 | PHASE4 | WITHDRAWN | A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A |
| NCT03359746 | PHASE4 | UNKNOWN | Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant |
| NCT03585101 | PHASE4 | WITHDRAWN | A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk |
| NCT03823911 | PHASE4 | COMPLETED | Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication |
| NCT02092350 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) |
| NCT02105701 | PHASE3 | COMPLETED | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) |
| NCT02115321 | PHASE2/PHASE3 | COMPLETED | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059) |
| NCT02203149 | PHASE2/PHASE3 | COMPLETED | Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) |
| NCT02204475 | PHASE3 | WITHDRAWN | Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) |
| NCT02251990 | PHASE3 | COMPLETED | Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) |
| NCT02252016 | PHASE3 | COMPLETED | Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) |
| NCT02358044 | PHASE3 | COMPLETED | Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) |
| NCT02600325 | PHASE3 | COMPLETED | Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV |
| NCT02890719 | PHASE3 | WITHDRAWN | Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. |
| NCT02897596 | PHASE3 | UNKNOWN | Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients |
| NCT02973503 | PHASE3 | COMPLETED | Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis |
| NCT04546802 | PHASE3 | WITHDRAWN | HepATocellular Cancer Hcv Therapy Study |
| NCT01717326 | PHASE2 | COMPLETED | A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) |
| NCT01932762 | PHASE2 | COMPLETED | Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) |
| NCT02105454 | PHASE2 | COMPLETED | Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048) |
| NCT02332707 | PHASE2 | COMPLETED | Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) |
| NCT02332720 | PHASE2 | COMPLETED | Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) |
| NCT02601573 | PHASE2 | COMPLETED | Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) |
| NCT02647632 | PHASE2 | COMPLETED | Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir |
| NCT02886624 | PHASE2 | COMPLETED | Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 |
| NCT02940496 | PHASE2 | COMPLETED | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma |
| NCT03379506 | PHASE2 | COMPLETED | Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) |
| NCT01532973 | PHASE1 | COMPLETED | Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002) |
| NCT01797536 | PHASE1 | COMPLETED | The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009) |
| NCT01937975 | PHASE1 | COMPLETED | The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) |
| NCT02333292 | Not specified | COMPLETED | Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions |
| NCT03110055 | Not specified | UNKNOWN | the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC. |
| NCT03145623 | Not specified | COMPLETED | Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease |
| NCT03407703 | Not specified | UNKNOWN | Hepatitis C (HCV) Cure and Kidney Health |
| NCT03433326 | Not specified | UNKNOWN | Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).